JNJ-1013 effectively targeted IRAK1 in terms of degradation, with a DC50 of 3.3 nM, and showed enhanced cytotoxicity (IC50 = 60 nM) in the ABC-DLBCL cell line HBL1. The gene discussed is IRAK1; the disease is diffuse large B-cell lymphoma.